| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$32.18 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
1,788 |
1,788 |
12,464 |
117,983 |
| Total Sell Value |
$97,772 |
$97,772 |
$588,604 |
$11,227,385 |
| Total People Sold |
2 |
2 |
12 |
18 |
| Total Sell Transactions |
2 |
2 |
26 |
70 |
| End Date |
2024-03-09 |
2023-12-07 |
2023-06-08 |
2022-06-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Flynn Karen |
Pres. Biologics & CCO |
• – – |
2021-01-11 |
4 |
AS |
$112.14 |
$278,279 |
D/D |
(2,478) |
34,544 |
|
-10% |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2021-01-06 |
4 |
AS |
$104.78 |
$6,392 |
D/D |
(61) |
16,509 |
|
-4% |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$12,530 |
D/D |
(120) |
16,570 |
|
-3% |
|
| Maselli Alessandro |
President & COO |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$15,454 |
D/D |
(148) |
19,618 |
|
-3% |
|
| Pravda Ricardo |
SVP & Chief HR Officer |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$8,145 |
D/D |
(78) |
13,870 |
|
-3% |
|
| Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$1,671 |
D/D |
(16) |
38,602 |
|
-3% |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$17,960 |
D/D |
(172) |
54,427 |
|
-3% |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$19,735 |
D/D |
(189) |
73,307 |
|
-3% |
|
| Flynn Karen |
Pres. Biologics & CCO |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$10,338 |
D/D |
(99) |
37,022 |
|
-3% |
|
| Gennadios Aristippos |
President Softgel & Oral Tech |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$11,486 |
D/D |
(110) |
51,315 |
|
-3% |
|
| Schmidt Kay A |
SVP, Technical Operations |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$7,623 |
D/D |
(73) |
15,266 |
|
-3% |
|
| Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$13,157 |
D/D |
(126) |
17,076 |
|
-3% |
|
| Whitlow Ricci S |
President, CSS |
• – – |
2021-01-04 |
4 |
AS |
$104.42 |
$8,667 |
D/D |
(83) |
3,268 |
|
-3% |
|
| Gennadios Aristippos |
President Softgel & Oral Tech |
• – – |
2020-12-21 |
4 |
AS |
$102.80 |
$1,405,044 |
D/D |
(13,662) |
51,425 |
|
8% |
|
| Gennadios Aristippos |
President Softgel & Oral Tech |
• – – |
2020-12-21 |
4 |
OE |
$24.44 |
$446,526 |
D/D |
13,662 |
61,151 |
|
- |
|
| Chiminski John R |
Chair & CEO |
• • – |
2020-12-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
163,618 |
|
- |
|
| Zippelius Peter |
Director |
– • – |
2020-11-23 |
4 |
S |
$99.26 |
$535,237,713 |
I/I |
(5,392,280) |
0 |
|
-7% |
|
| Zippelius Peter |
Director |
– • – |
2020-11-23 |
4 |
OE |
$49.54 |
$267,138,404 |
I/I |
5,392,280 |
5,392,280 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2020-11-11 |
4 |
S |
$100.99 |
$244,901 |
D/D |
(2,425) |
73,496 |
|
-1% |
|
| Zippelius Peter |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
6,428 |
|
- |
|
| Lucier Gregory T |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
19,707 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
14,897 |
|
- |
|
| Classon Rolf A |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
30,777 |
|
- |
|
| Crane Rosemary A |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
11,329 |
|
- |
|
| Stahl Jack L |
Director |
– • – |
2020-10-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,125 |
30,777 |
|
- |
|
821 Records found
|
|
Page 13 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.74 (1.33%) 
